Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of FDA022-BB05 in Advanced Solid Tumors
NCT05564858Phase 1Recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of FDA022-BB05 in solid tumor, breast cancer, gastric cancer (GC) and 1 more (2 arms), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Jan 2023; status: recruiting.
02
Drugs
FDA022-BB05
03
Conditions
solid tumorbreast cancergastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05564858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05564858.